Wire

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

News Plus

Welcome, one more step

The cross-newsroom layer: who covered a story, who didn’t, and how each one worded it. Plus your own news, on every device.

Follow your news

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories
  • The daily brief by email

See the coverage

  • Headlines side by side
  • Who reported first
  • Every newsroom clip, from every platform
  • Every newsroom photo on a story

Go deeper

  • The whole archive
  • Your reading diet
  • Duki without the daily limit
  • The Desk: the news, spoken every hour
  • Catch Me Up, and what changed since you read it
  • The Wire

Free stays free: the live wire, Not Everywhere, the brief, five follows and five Duki questions a day.

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

News Plus · Ask Duki

Keep asking Duki

A free account gets five questions a day. News Plus lifts the daily limit.

Also in News Plus

  • The whole archive
  • Headlines side by side
  • Who reported first
  • The Desk, every hour
Channel 13Health

Teva Announces Positive Early Trial Results for New Celiac Disease Antibody

Translated & summarized from Channel 13 by baba

CenterNeutral tone

Hebrew · 15 newsrooms covering

Teva Pharmaceuticals reported positive early clinical trial results for a new antibody treatment for celiac disease. The experimental drug aims to protect against accidental gluten exposure, complementing, not replacing, strict gluten-free diets. Professor Eitan Friedman also clarified that gluten-free diets offer no health benefits for those without celiac disease.

The story in 5 lines · by baba

  • Teva Pharmaceuticals reports positive early trial results for a new celiac disease antibody.
  • The experimental antibody aims to protect against accidental gluten exposure.
  • The treatment is intended to supplement, not replace, gluten-free diets.
  • Celiac disease affects about one percent of the world's population.
  • Gluten-free diets offer no health benefits for people without celiac disease.
Teva Announces Positive Early Trial Results for New Celiac Disease Antibody
Editorial illustration generated by baba News, not a photograph of the event.

Teva Pharmaceuticals has announced positive preliminary results from an early-stage clinical trial for a new antibody treatment aimed at celiac disease. This development offers potential new hope for millions of celiac patients worldwide who currently rely solely on strict gluten-free diets.

Professor Eitan Friedman, speaking on the program "HaOlam HaBoker," explained that celiac disease affects approximately one percent of the global population. He detailed the experimental antibody's mechanism of action and the trial's findings, emphasizing that the treatment is not intended to replace a gluten-free diet entirely.

Instead, the experimental antibody's primary goal is to provide protection against accidental gluten exposure, such as from cross-contamination. This offers an essential layer of defense for patients during unintentional gluten intake, while maintaining a strict gluten-free diet remains the cornerstone of managing the condition.

Professor Friedman also addressed and debunked the common misconception that gluten-free diets are healthier for individuals without celiac disease. He stated unequivocally, "Those people who say 'I eat foods labeled gluten-free because it's healthier,' this statement has no factual basis." His remarks aimed to clarify the critical medical necessity of gluten-free diets for celiac patients versus the unfounded trend among healthy individuals to consume gluten-free products.

Channel 13Centre · Tel Aviv

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

News Plus · Follows

You’ve used your five follows

News Plus follows as many newsrooms, topics and people as you like, with alerts for each in the app.

Your follows5 of 5 on the free plan
Or swap one out in Following

Also in News Plus

  • Alerts for what you follow
  • Hide read stories
  • The daily brief by email
  • Your reading diet
HealthTopic

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

News Plus · Follows

You’ve used your five follows

News Plus follows as many newsrooms, topics and people as you like, with alerts for each in the app.

Your follows5 of 5 on the free plan
Or swap one out in Following

Also in News Plus

  • Alerts for what you follow
  • Hide read stories
  • The daily brief by email
  • Your reading diet

Mentioned

Full coverage · 17 outlets
First: Bizportal · Sep 2

The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.

Open the Wire